Increased Scheme Consideration from Pfizer • ResApp Health and Pfizer have agreed to increase the scheme consideration from A$0.115 per share in cash to: - A$0.207 per share in cash, upon satisfaction of a Confirmatory Data Readout Condition (Confirmed Data Consideration); or - A$0.146 per share in cash, in the event the Confirmatory Data Readout Condition is not satisfied (Unconfirmed Data Consideration) • Relative to ResApp’s share price prior to announcement of the Initial Scheme, the Revised Scheme Consideration represents a material premium of: - 130.0% based on the Confirmed Data Consideration - 62.2% based on the Unconfirmed Data Consideration • Draft Independent Expert Report confirms that Revised Scheme is fair and reasonable and in best interests of ResApp shareholders • The ResApp Board unanimously recommends that ResApp shareholders vote in favour of the Revised Scheme
RAP Price at posting:
11.0¢ Sentiment: Hold Disclosure: Held
